Prosonix is a specialty pharmaceutical company based in Oxford, UK, led by CEO David Hipkiss. It develops a portfolio of inhaled respiratory medicines by reformulating known and approved drugs using its own particle engineering technology. Its lead products include PSX1001, a generic drug for asthma, and PSX1002 for chronic obstructive pulmonary disease. The company is also advancing development of next‑generation combination respiratory medicines. Prosonix intends to use financing proceeds to advance its proprietary product pipeline of therapies. Prosonix Ltd. is an Oxford, UK-based developer of high-value respiratory therapies enabled by its novel and proprietary particle engineering technology. The company's patented particle engineering technology provides an opportunity to develop novel and generic mono and combination respiratory medicines efficiently in a range of affordable and commercially available Metered Dose and Dry Powder Inhalers. Prosonix has commercialized its technology via partnering with a range of originator, specialty, device and generic pharma companies. It intends to use the £11.4m financing to advance its emerging proprietary product pipeline of mono and multi-component combination therapies and to support Phase 2 clinical trials as required. Founded in early 2006, Prosonix combines proprietary development with partner-led commercialization strategies. In conjunction with the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join Prosonix’s Board of Directors.

Total raised

$45M

Funding rounds

2

Latest round

Series B

Latest activity

May 2012